Study Fails To Support Broader Patient Population For Cardiac-Resynchronization Therapy

Cardiac-resynchronization therapy (an advanced feature of pacemakers and ICDs manufactured by Medtronic, Boston Scientific, St. Jude Medical, Biotronik, and Sorin) has been shown to be beneficial in heart failure (HF) patients with a wide QRS interval. These benefits have not been reproduced so far in patients with narrow QRS intervals, though many such patients have ventricular dyssynchrony. Now a new study, presented at the European Society of Cardiology in Amsterdam and published simultaneously in the New England Journal of Medicine, once again has failed to find benefits for CRT in a broader patient population.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news